Jin Medical closes US$159.42 million VIE control acquisition of Huaxia Qiying

• Closing completed on Sept. 24, 2026 for a VIE-control acquisition of Huaxia Qiying through Erhua Medical Technology (Changzhou).
• Aggregate consideration set at USD 159.42 million, combining 71,282,488 Class A shares with non-share assets and interests.
• Separate advisory fee paid in 8,479,560 Class A shares to Veltrion Haskel Holdings and designee Quinnet Section.
• Post-closing share count reached 158,194,533, including 153,425,476 Class A shares and 4,769,057 Class B shares.
• Kangma Equity transfer targeted by Sept. 30, 2026; failure by Oct. 31 triggers 622,123 Class A shares as substitute.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jin Medical International Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-103071), on September 24, 2026, and is solely responsible for the information contained therein.